Trust Signals
Conflicts of interest: FormBlends sells research peptides. We disclose this and apply a higher evidentiary bar precisely because of it.
What this page will not do: Overstate clinical outcomes. Every confidence rating in the evidence ledger below is deliberately conservative.
Regulatory note: GHRP-2 is not FDA-approved for human therapeutic use. Nothing here constitutes medical advice.
Key Takeaways
- GHRP-2 is a synthetic hexapeptide (6 amino acids, MW 817.94 g/mol) that binds the ghrelin receptor GHS-R1a to produce a dose-dependent GH pulse peaking around 1 mcg/kg.
- Human pharmacology data confirm reliable GH elevation; controlled evidence for downstream outcomes (muscle, fat loss) in healthy adults is absent.
- At supratherapeutic doses, GHRP-2 raises cortisol and prolactin, not just GH, a tradeoff most vendor pages do not mention.
- A valid COA must include HPLC purity above 98%, mass spec confirmation at 817.94 g/mol, and endotoxin (LAL) testing. Absence of the last item is a sourcing disqualifier.
- GHRP-2 is on the WADA prohibited list. Competitive athletes should treat detection risk as real and non-trivial.
What Is GHRP-2 and Should You Buy It? (Direct Answer)
Buy GHRP-2 only if your goal is reliably amplifying GH pulses for research or clinical-adjacent use under medical oversight, and you can source a product with HPLC purity above 98% plus endotoxin data. The GH-raising mechanism is well-characterized in humans. Downstream body-composition benefits in healthy adults remain unproven in controlled trials. Evidence is moderate for mechanism, very low for performance outcomes.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What exactly is GHRP-2?
- Evidence Ledger: What does the research actually show?
- How does GHRP-2 work, with specific numbers?
- What most GHRP-2 pages get wrong
- The chemistry behind storage and stability rules
- Honest head-to-head: GHRP-2 vs GHRP-6 vs sermorelin
- Dosing and reconstitution: operational guide
- How to read a COA and evaluate a supplier
- Side effects and failure modes
- Legal status, WADA, and regulatory reality
- FAQ
- Sources
What Exactly Is GHRP-2?
GHRP-2 (growth hormone releasing peptide-2), also called pralmorelin in some clinical literature, is a synthetic six-amino-acid peptide with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. Its molecular weight is 817.94 g/mol and its molecular formula is C45H55N9O6. It was developed in the 1980s and 1990s as part of a research program to find orally or parenterally active GH secretagogues, and it reached Phase II clinical trials in Japan under the name pralmorelin before commercial development was discontinued.
It is distinct from GHRH (growth hormone releasing hormone): GHRH acts at a different receptor (GHRHR) and works through a different intracellular pathway. GHRP-2 acts primarily at GHS-R1a, the ghrelin receptor. The two mechanisms are complementary, which is why combining a GHRP with a GHRH analog produces synergistic rather than merely additive GH pulses.
Evidence Ledger: What Does the Research Actually Show?
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| GHRP-2 raises serum GH acutely in humans | Human RCTs and crossover pharmacology studies (Bowers et al., Ghigo et al.) | Strong positive, dose-dependent to approx. 1 mcg/kg | High |
| GHRP-2 raises IGF-1 with repeated dosing | Human trials in GH-deficient and elderly populations | Positive; magnitude varies by baseline GH status | Moderate |
| GHRP-2 elevates cortisol and prolactin at doses at or above 1 mcg/kg | Human pharmacology studies (Arvat et al. 1997) | Positive (unwanted) elevation confirmed | High |
| GHRP-2 improves body composition (muscle gain, fat loss) in healthy adults | Mechanistic inference; no controlled human trial in healthy trained adults | Plausible direction, unproven magnitude | Very Low |
| GHRP-2 plus GHRH analog produces synergistic GH pulse | Human crossover pharmacology studies | Strongly positive vs either agent alone | High |
| GHRP-2 improves sleep quality | Animal data and one small human study on GH pulse timing | Weak positive signal, low sample sizes | Low |
| GHRP-2 has cardiac or anti-fibrotic effects | Rodent and cell culture data only | Positive in animal models; no human translation confirmed | Low |
| Long-term safety in healthy adults is established | No long-term controlled trial exists in this population | Unknown | Very Low |
How Does GHRP-2 Work? (Specific Numbers)
GHRP-2 is a full agonist at GHS-R1a, the ghrelin receptor, with high binding affinity. GHS-R1a is a G-protein-coupled receptor (Gq subtype) expressed on pituitary somatotrophs and hypothalamic neurons. Activation triggers phospholipase C, raises intracellular calcium, and drives GH granule exocytosis.
A second mechanism: GHRP-2 partially blunts somatostatin release from the hypothalamus. Somatostatin is the primary brake on GH secretion, so removing it amplifies the net pulse. This dual action (stimulate the accelerator, ease the brake) is why GHRP-2 produces larger GH peaks than agents that work through only one pathway.
Dose-response data from human pharmacology studies show the GH response rises from roughly 0.1 mcg/kg through approximately 1 mcg/kg, after which the curve flattens. The GH peak typically occurs within 15 to 30 minutes of injection and returns to near-baseline within 90 to 120 minutes. This short pulse mimics, but amplifies, a physiological secretory event.
What this mechanism does NOT prove: a sharp GH pulse in a pharmacology study does not automatically translate to meaningful changes in lean mass or adipose tissue in a healthy, well-nourished adult with normal GH axis function. IGF-1 changes with chronic use have been documented in deficient populations. Extrapolating those data to healthy users is speculative.
What Most GHRP-2 Pages Get Wrong
Tachyphylaxis is real. GHS-R1a downregulates with repeated pulsatile stimulation. Continuous exposure (as would happen with too-frequent dosing) blunts the GH response. This is why dosing protocols typically use spacing of several hours between injections, not because of tradition but because receptor resensitization requires time.
Peptide purity at the vial level is not the same as purity at the point of injection. Even a 99% pure lyophilized product degrades after reconstitution. Every vendor promotes purity at manufacture. Almost none discusses post-reconstitution degradation kinetics or endotoxin load, which is the actual safety-limiting factor for injectable peptides.
The Chemistry Behind Storage and Stability Rules
GHRP-2's six-amino-acid chain contains a D-2-naphthylalanine residue and a tryptophan residue. Tryptophan (Trp) is particularly susceptible to photo-oxidation: UV and visible light drive oxidation of the indole ring, generating kynurenine and other degradation products. This is why amber vials or dark storage is not optional.
In aqueous solution, the peptide bond is also subject to hydrolysis, accelerated by heat and extremes of pH. Bacteriostatic water (0.9% benzyl alcohol) slows microbial growth but does not arrest chemical degradation. At refrigerator temperature (2 to 8 degrees Celsius), hydrolysis proceeds slowly enough that a 28 to 30 day use window is practically reasonable. At room temperature that window shortens meaningfully. Freeze-thaw cycling subjects the peptide to ice crystal shear and concentration stress at phase boundaries, fragmenting the chain over multiple cycles.
Lyophilized (freeze-dried) GHRP-2 is far more stable because removing water stops both hydrolysis and most oxidation pathways. Lyophilized product properly sealed under nitrogen or argon can remain stable for 12 to 24 months at refrigerated temperatures. The moment you add water, the clock starts.
Why does this matter when buying? A vendor who ships reconstituted peptide, or who cannot confirm lyophilization process and packaging atmosphere, is selling a product with unknown remaining activity.
Honest Head-to-Head: GHRP-2 vs GHRP-6 vs Sermorelin
| Feature | GHRP-2 | GHRP-6 | Sermorelin |
|---|---|---|---|
| Receptor target | GHS-R1a (ghrelin receptor) | GHS-R1a (ghrelin receptor) | GHRHR (GHRH receptor) |
| GH pulse strength | Strong; comparable or slightly superior to GHRP-6 | Strong; slightly weaker pulse than GHRP-2 at equal dose | Moderate; more physiological amplitude |
| Hunger/appetite side effect | Mild to moderate | Significant; strongest hunger of the three | Minimal |
| Cortisol and prolactin elevation | Yes, documented in human studies | Yes, similar profile to GHRP-2 | Not a known feature at therapeutic doses |
| Human clinical trial data | Moderate; Phase II data (pralmorelin) | Moderate pharmacology data; less clinical trial history | More extensive; FDA-approved formulations existed (Geref, now discontinued) |
| GHRH synergy when combined | Yes, well-documented | Yes, well-documented | N/A (it is the GHRH analog) |
| Where GHRP-2 loses | GHRP-2 loses on HPA-axis cleanliness compared to sermorelin. It loses on appetite control compared to nothing (sermorelin causes essentially no hunger). If avoiding cortisol/prolactin elevation is the priority, sermorelin or ipamorelin (not reviewed here) are better choices. | ||
Dosing and Reconstitution: Operational Guide
Dosing Reference Table
| Goal | Dose per injection | Frequency | Notes |
|---|---|---|---|
| Diagnostic GH stimulation (research) | 1 mcg/kg body weight | Single administration | Standard pharmacological test dose; cortisol/prolactin rise expected at this level |
| Pulsatile GH amplification, moderate | 100 to 200 mcg flat dose | Once to twice daily, spaced at least 3 hours apart | Below the cortisol-elevation threshold seen in pharmacology studies; hunger mild |
| Combined protocol with GHRH analog | 100 mcg GHRP-2 plus 100 mcg GHRH analog | Once daily, before sleep | Synergistic pulse; do not dose more than 1 to 2 times daily to avoid tachyphylaxis |
Reconstitution Math
Standard vial: 5 mg (5000 mcg) lyophilized GHRP-2. Add 1 mL bacteriostatic water. Resulting concentration: 5000 mcg/mL (5 mcg per microliter). To draw 100 mcg: pull 20 microliters (0.02 mL) into a U-100 insulin syringe, which reads as 2 units on the syringe scale. To draw 200 mcg: pull 40 microliters (4 units on U-100 syringe).
If you prefer a more dilute solution for precision with small syringes, add 2 mL bacteriostatic water to a 5 mg vial: concentration becomes 2500 mcg/mL. Then 100 mcg requires 40 microliters (4 units on U-100).
Inject subcutaneously into abdominal skin fold. Rotate sites. Administer on an empty stomach or at least 1 to 2 hours after a meal; dietary fat and carbohydrates blunt the GH pulse by raising endogenous insulin and somatostatin.
How to Read a COA and Evaluate a Supplier
When you buy GHRP-2 peptide for sale online, the certificate of analysis (COA) is the only objective check you have. Here is what a legitimate COA must contain and what to do with it.
| COA Element | What to Look For | Red Flag |
|---|---|---|
| HPLC purity | Above 98%, with a chromatogram showing peak identity and integration | Purity stated without a chromatogram; purity below 98% |
| Mass spectrometry | Confirmed molecular ion at 817.94 g/mol (or 818 as integer) for GHRP-2 | Mass spec absent; wrong molecular weight; vendor cannot explain discrepancy |
| Endotoxin (LAL test) | Below 5 EU/mg for research injectables; ideally below 1 EU/mg | Endotoxin not tested at all; this is the biggest safety omission for injectables |
| Residual solvents | Acetonitrile, TFA, DMF below USP Class 2 limits | No residual solvent data; TFA salt not acknowledged (affects net peptide mass) |
| Batch number on COA matches vial label | Traceable lot number | Generic COA not tied to the specific batch you received |
| Third-party testing | COA issued by an independent analytical lab, not the manufacturer | COA issued by the same company that synthesized the peptide |
One additional point most buyers miss: GHRP-2 is commonly sold as a trifluoroacetate (TFA) salt from solid-phase peptide synthesis. TFA content can represent a meaningful fraction of the stated vial mass, meaning a "5 mg" vial may contain less than 5 mg of actual peptide. Quality suppliers convert to acetate salt or clearly disclose TFA content and report net peptide mass separately.
Side Effects and Failure Modes
Documented in human studies: transient hunger (most common), water retention (particularly early in use), injection-site erythema, cortisol elevation at higher doses, prolactin elevation at higher doses, transient dizziness after injection.
Documented in animal or in vitro data but not confirmed in controlled human trials: effects on cardiac tissue (studied in rodent ischemia models), effects on fibrosis pathways, neurological effects beyond GH secretion.
Failure modes specific to GHRP-2:
- Tachyphylaxis with excessive dosing frequency: spacing injections less than 3 hours apart reduces receptor availability and blunts subsequent GH pulses.
- Insulin blunting: injecting GHRP-2 within 1 hour of a meal containing carbohydrates or fat significantly reduces the GH response because postprandial insulin raises somatostatin tone.
- Product degradation: a reconstituted vial kept at room temperature, or shaken rather than swirled, loses bioactivity in ways invisible to the user. The solution looks the same but the peptide chain is fragmented.
- Contamination risk: endotoxin (bacterial lipopolysaccharide) contamination from low-quality synthesis causes injection-site inflammation, fever, and in severe cases systemic inflammatory response. This is the primary safety risk of sourcing from vendors without LAL testing.
Legal Status, WADA, and Regulatory Reality
GHRP-2 is not FDA-approved for human use. It is not a scheduled controlled substance under the US Controlled Substances Act as of this writing, placing it in a regulatory grey zone often described as a "research chemical." Purchasing for personal human use is technically outside labeled use; enforcement has historically focused on commercial distributors rather than individual buyers, but this can change.
WADA includes GHRP-2 explicitly on its prohibited list under Section 2 (Peptide Hormones, Growth Factors, Related Substances). Any athlete subject to WADA-compliant anti-doping testing, including those competing under national anti-doping programs, should treat GHRP-2 as a prohibited substance with real detection consequences. Detection windows vary by method and dose, and analytical methods have improved substantially in recent years.
Compounded GHRP-2 from a 503B outsourcing facility or under physician supervision occupies a different legal category, though FDA has increasingly scrutinized compounded peptides. Patients pursuing this route should work with a licensed physician and a licensed compounding pharmacy.
FAQ
Is GHRP-2 for sale legally in the United States?
GHRP-2 is not FDA-approved for human therapeutic use. It is sold legally as a research chemical or compounded preparation for investigational purposes. Purchasing for human self-administration exists in a regulatory grey zone that varies by jurisdiction.
What does GHRP-2 actually do in the body?
GHRP-2 binds the ghrelin receptor (GHS-R1a) and, secondarily, blunts somatostatin signaling. This produces a short, sharp pulse of GH release from pituitary somatotrophs. The pulse is dose-dependent up to roughly 1 mcg per kg body weight.
What is the effective dose range for GHRP-2?
Human studies have used doses from 0.1 mcg/kg to 1 mcg/kg administered subcutaneously or intravenously. The dose-response curve flattens above approximately 1 mcg/kg, and going higher adds prolactin and cortisol release without proportionally more GH.
How does GHRP-2 compare to GHRP-6?
GHRP-2 produces a somewhat stronger and cleaner GH pulse than GHRP-6 at equivalent doses. GHRP-6 causes significantly more hunger due to stronger ghrelin-mimetic activity in the gut. GHRP-2 still raises cortisol and prolactin; neither is cleaner than sermorelin in that respect.
Does GHRP-2 raise IGF-1 levels?
Repeated GH pulses from GHRP-2 can raise circulating IGF-1 over time. Human trial data show significant IGF-1 increases with chronic GHRP-2 administration in GH-deficient populations, but effect magnitude in healthy adults with normal baseline GH is less well characterized.
What are the main side effects of GHRP-2?
The most consistent side effects are transient hunger, water retention, and injection-site reactions. Elevated cortisol and prolactin are documented in human pharmacology studies. Long-term safety in healthy adults has not been studied in controlled trials.
How should GHRP-2 peptide be stored after reconstitution?
Lyophilized GHRP-2 is stable at room temperature for short periods but should be stored at 2 to 8 degrees Celsius and shielded from light. After reconstitution with bacteriostatic water, refrigerate and use within 28 to 30 days. Freeze-thaw cycling degrades the peptide chain.
What should a GHRP-2 certificate of analysis include?
A valid COA should show HPLC purity above 98%, mass spectrometry confirmation of the correct molecular weight (817.94 g/mol for GHRP-2), residual solvent testing, and endotoxin (LAL) testing. Absence of endotoxin data is a significant red flag for injectable research peptides.
Can GHRP-2 be stacked with a GHRH analog?
Co-administration of GHRP-2 with a GHRH analog (such as CJC-1295 or sermorelin) produces a synergistic GH pulse that is larger than either agent alone. This is a well-documented pharmacological interaction in published human studies, though long-term safety of the combination remains uncharacterized.
Will GHRP-2 show up on a drug test?
GHRP-2 is listed on the WADA prohibited list under the category of peptide hormones and growth factors. Competitive athletes subject to anti-doping testing should treat GHRP-2 as a detectable prohibited substance.
How do I reconstitute GHRP-2 powder?
Add bacteriostatic water slowly down the vial wall, do not inject directly onto the lyophilized cake, and swirl gently without shaking. A common starting dilution is 1 mL of bacteriostatic water per 5 mg vial, yielding 5000 mcg/mL, which you then draw in small volumes per dose.
Is GHRP-2 effective for bodybuilding or fat loss?
Human trials show GHRP-2 reliably raises GH. Whether that GH pulse translates to meaningful muscle gain or fat loss in healthy, trained adults has not been demonstrated in controlled trials. The mechanistic chain is plausible but the clinical outcome evidence is very low quality.
Sources
- Bowers CY. Growth hormone releasing peptides: history and mechanisms of action. In: Bercu BB, Walker RF, eds. Growth Hormone Secretagogues. Springer, 1996. (Original GHRP series pharmacology.)
- Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445-460. (Comprehensive early human pharmacology review.)
- Arvat E, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Eur J Endocrinol. 1997;136(4):369-374. (Primary source for cortisol and prolactin elevation data.)
- Arvat E, et al. Preliminary evidence that GH-releasing peptide can act synergistically with GH-releasing hormone to enhance GH secretion in normal human subjects. J Clin Endocrinol Metab. 1995;80(12):3692-3698. (Synergy with GHRH analogs.)
- Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005;85(2):495-522. (GHS-R1a mechanism and ghrelin receptor biology.)
- Smith RG, et al. A role for the growth hormone releasing hexapeptide-6 in the modulation of GH secretion, IGF-I, and body composition. Endocr Rev. 1997;18(5):621-645. (GHS receptor pathway and downstream IGF-1 effects.)
- WADA Prohibited List 2024. World Anti-Doping Agency. Available at: wada-ama.org. (GHRP-2 listing under S2 peptide hormones.)
- USP General Chapter <1> Injections and Implanted Drug Products. United States Pharmacopeia. (Endotoxin and sterility standards for injectable preparations.)
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. (Context for GHS clinical outcomes in aging populations.)
- Locatelli V, Bianchi VE. Effect of GH/IGF-1 on bone metabolism and osteopenia. Int J Endocrinol. 2014;2014:235060. (Downstream IGF-1 physiology context.)